<DOC>
	<DOCNO>NCT02735356</DOCNO>
	<brief_summary>This phase 0 trial study well itraconazole gel work treat patient basal cell cancer . Itraconazole gel may help treat basal cell tumor patient .</brief_summary>
	<brief_title>Topical Itraconazole Treating Patients With Basal Cell Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine 12 week topical itraconazole gel reduces basal cell carcinoma ( BCC ) biomarkers ( Gli1 , target gene Hedgehog pathway ) . SECONDARY OBJECTIVES : I . To determine topical itraconazole gel decrease BCC size . OUTLINE : Patients apply itraconazole topically twice daily ( BID ) placebo topically BID 12 week . After completion study treatment , patient follow 14 week .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>The subject must sign date inform consent statement ; child sign assent form guardian sign consent form The subject must willing apply medication twice daily 1 month The subject must least four BCCs noncosmetically sensitive site For woman childbearing potential , negative urine pregnancy test Women childbearing potential expect use effective method birth control prevent expose fetus potentially dangerous agent unknown risk For male patient female partner childbearing potential , agreement use adequate contraception participate study 1 month apply last dose Pregnancy breastfeed History congestive heart failure finding ventricular dysfunction History current evidence malabsorption liver disease Current immunosuppression take immunosuppressive drug Taking oral itraconazole Taking medication know affect hedgehog ( HH ) signal pathway The subject use topical systemic therapy might interfere evaluation study medication study ; specifically include topical use study tumor : glucocorticoid ( ii ) retinoids ( e.g. , etretinate , isotretinoin , tazarotene , tretinoin , adapalene ) systemically topically ( iii ) alphahydroxy acid ( e.g. , glycolic acid , lactic acid ) 5 % skin six month prior study entry ( iv ) 5fluorouracil imiquimod ; also treatment systemic chemotherapy agent know inhibitor HH signal within 60 day start study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>